α5‐nAChR and survivin: Two potential biological targets in lung adenocarcinoma,Journal of Cellular Physiology

当前位置： X-MOL 学术 › J. Cell. Physiol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

α5‐nAChR and survivin: Two potential biological targets in lung adenocarcinoma
Journal of Cellular Physiology ( IF 4.5 ) Pub Date : 2020-07-28 , DOI: 10.1002/jcp.29956
Yujie Zhang _{1,

2} , Yilin Sun ₃ , Yanfei Jia ₁ , Qian Zhang ₄ , Ping Zhu ₂ , Xiaoli Ma _{1,

4}

Affiliation

Recent studies have shown that the overexpression of α5 nicotinic acetylcholine receptor (α5‐nAChR) is associated with nicotine‐related lung carcinogenesis. Survivin is one of the biomarkers of a worse prognosis for smoking‐related lung cancer. The aim of this study is to investigate the association of α5‐nAChR, survivin, and clinical outcomes in lung adenocarcinoma (LUAD). We analyzed the expression level and correlation of CHRNA5 (encoding α5‐nAChR) and BIRC5 (encoding survivin) in LUAD with The Cancer Genome Atlas data set. The relationship between overall survival (OS) and the expression of CHRNA5 or/and BIRC5 was evaluated by the Kaplan–Meier method and Cox proportional hazards model. Moreover, our results showed that the expression of α5‐nAChR mediated survivin expression in lung cancer cells and in lung tumor xenografts. Relationships between the expression of α5‐nAChR and/or survivin with clinical‐pathological characteristics were analyzed using LUAD tissue samples. The results showed that expression of α5‐nAChR was correlated with survivin expression in vitro and in vivo. The group coexpressing α5‐nAChR and survivin had a worse prognosis than other subgroups in LUAD (p < .05). In conclusion, ascertaining the expression of both α5‐nAChR and survivin provides a better measure of prognosis for LUAD patients. The combined inhibition of α5‐nAChR and survivin may be a promising multitargeted gene therapeutic strategy in LUAD diagnosis.

中文翻译：

α5-nAChR 和存活蛋白：肺腺癌的两个潜在生物学靶点

最近的研究表明，α5 烟碱乙酰胆碱受体 (α5-nAChR) 的过度表达与尼古丁相关的肺癌发生有关。Survivin 是吸烟相关肺癌预后较差的生物标志物之一。本研究的目的是调查 α5-nAChR、存活蛋白和肺腺癌 (LUAD) 临床结果的关联。我们使用癌症基因组图谱数据集分析了 LUAD 中 CHRNA5（编码 α5-nAChR）和 BIRC5（编码 survivin）的表达水平和相关性。通过Kaplan-Meier方法和Cox比例风险模型评估总生存期（OS）与CHRNA5或/和BIRC5表达之间的关系。此外，我们的结果表明，α5-nAChR 的表达介导了肺癌细胞和肺肿瘤异种移植物中存活蛋白的表达。使用 LUAD 组织样本分析了 α5-nAChR 和/或存活蛋白的表达与临床病理特征之间的关系。结果表明，α5-nAChR 的表达与体外和体内 survivin 的表达相关。在 LUAD 中，α5-nAChR 和存活蛋白共表达组的预后比其他亚组差。p < .05）。总之，确定 α5-nAChR 和存活蛋白的表达为 LUAD 患者的预后提供了更好的衡量标准。α5-nAChR 和存活蛋白的联合抑制可能是 LUAD 诊断中一种有前景的多靶点基因治疗策略。

更新日期：2020-07-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11